Clinical Trial Update: Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating tocilizumab for severe pneumonitis due to SARS-CoV-2 (COVID-19).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Università Politecnica delle Marche | Conditions: SARS Pneumonia | Phase 2 | Status: UNKNOWN